Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division
Department of Medicine
Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
Medical Director, Stanford Medical Center Transfer Center, Stanford University Medical Center
Stanford, California

Related Videos

Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC? Video

Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC?

Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy? Video

Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease? Video

Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease? Video

Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen? Video

Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?

What are the specific recommendations and concrete guidelines—albeit 12 years old—for treatment for MAC lung disease? Is there flexibility as far as dosing frequency? Video

What are the specific recommendations and concrete guidelines—albeit 12 years old—for treatment for MAC lung disease? Is there flexibility as far as dosing frequency?

How do you put together the triad of critical data sets—stability or progression of disease by spirometry, radiographic findings and symptoms/clinical fragility—to make a final determination to expose the patient to the “burden of treatment?” Video

How do you put together the triad of critical data sets—stability or progression of disease by spirometry, radiographic findings and symptoms/clinical fragility—to make a final determination to expose the patient to the “burden of treatment?”

What specific findings should mandate treatment and encourage the patient to embark on a course of antimicrobial therapy? How should this multi-factorial analysis evolve and how should the patient be engaged in the decision-making process? Video

What specific findings should mandate treatment and encourage the patient to embark on a course of antimicrobial therapy? How should this multi-factorial analysis evolve and how should the patient be engaged in the decision-making process?

How do you analyze the complex clinical, radiographic, and microbiologic data to determine whether the patient should be started on antibiotic treatment? Video

How do you analyze the complex clinical, radiographic, and microbiologic data to determine whether the patient should be started on antibiotic treatment?